Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 110 results for "Chronic Lymphocytic Leukemia (CLL)".

Thumbnail for Comparative Efficacy and Safety of Pirtobrutinib Versus Covalent BTK Inhibitors in Treatment-Naοve Chronic Lymphocytic Leukemia: A Systematic Review and Bayesian Network Meta-Analysis

CLL - 450

Comparative Efficacy and Safety of Pirtobrutinib Versus Covalent BTK Inhibitors in Treatment-Naοve Chronic Lymphocytic Leukemia: A Systematic Review and Bayesian Network Meta-Analysis

Pakeeza Saif

Poster Presenter: Pakeeza Saif

Thumbnail for Real-World Clinical Outcomes of Targeted Therapy in a Pakistani Cohort of Chronic Lymphocytic Leukemia

CLL - 465

Real-World Clinical Outcomes of Targeted Therapy in a Pakistani Cohort of Chronic Lymphocytic Leukemia

Munira Borhany

Poster Presenter: Munira Borhany

Previous 1...7 8 9 10 11 12 13 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Real-World Comparative Analysis of Treatment Discontinuation (TD) with Covalent Bruton Tyrosine Kinase Inhibitors (cBTKis) in First-Line (1L) Chronic Lymphocytic Leukemia (CLL)

CLL - 476

Real-World Comparative Analysis of Treatment Discontinuation (TD) with Covalent Bruton Tyrosine Kinase Inhibitors (cBTKis) in First-Line (1L) Chronic Lymphocytic Leukemia (CLL)

Derrick van Beuge

Poster Presenter: Derrick van Beuge

Thumbnail for How Many Lines of Therapy Do Patients With CLL/SLL Receive in Routine Clinical Practice in the United States? Real-World Evidence From the Targeted Therapy Era

CLL - 560

How Many Lines of Therapy Do Patients With CLL/SLL Receive in Routine Clinical Practice in the United States? Real-World Evidence From the Targeted Therapy Era

Deborah M. Stephens

Poster Presenter: Deborah M. Stephens

Thumbnail for Impact of Type 2 Diabetes on Cardiovascular Toxicity, Infectious Complications, and Survival Among Patients With Chronic Lymphocytic Leukemia Treated With BTK Inhibitors: A Propensity-Matched TriNetX Analysis

CLL - 580

Impact of Type 2 Diabetes on Cardiovascular Toxicity, Infectious Complications, and Survival Among Patients With Chronic Lymphocytic Leukemia Treated With BTK Inhibitors: A Propensity-Matched TriNetX Analysis

Jude Ossai

Poster Presenter: Jude Ossai

Thumbnail for Marrow-Dominant Aggressive Progression of TP53-Altered CLL/SLL After Reactive Myelofibrosis: A Diagnostic and Therapeutic Challenge

CLL - 620

Marrow-Dominant Aggressive Progression of TP53-Altered CLL/SLL After Reactive Myelofibrosis: A Diagnostic and Therapeutic Challenge

Adela Perolla

Poster Presenter: Adela Perolla

Thumbnail for Frequency and Factors Predisposing to Pulmonary Infections in Patients With Chronic Lymphocytic Leukemia Treated With Targeted Agents

CLL - 630

Frequency and Factors Predisposing to Pulmonary Infections in Patients With Chronic Lymphocytic Leukemia Treated With Targeted Agents

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for Retreatment With Venetoclax-Based Therapies in Relapsed Chronic Lymphocytic Leukemia: A Pool Analysis of Outcomes Based on Treatment-Free Intervals and Cytogenetics/Molecular Risks

CLL - 662

Retreatment With Venetoclax-Based Therapies in Relapsed Chronic Lymphocytic Leukemia: A Pool Analysis of Outcomes Based on Treatment-Free Intervals and Cytogenetics/Molecular Risks

Jun Chih Wang

Poster Presenter: Jun Chih Wang

Thumbnail for Frailty in Chronic Lymphocytic Leukemia: Evidence From the 2017-2022 Nationwide Inpatient Sample of the United States

CLL - 689

Frailty in Chronic Lymphocytic Leukemia: Evidence From the 2017-2022 Nationwide Inpatient Sample of the United States

Preetham Ezhilarasu

Poster Presenter: Preetham Ezhilarasu

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors